1 - FDA Memorandum: Revised Guideline for the Collection
of Platelets, Pheresis - 10/7/1988.
2 - FDA Recommendations and Licensure Requirements for Leukocyte-Reduced
Blood Products, May 29, 1996.
3 - FDA Memorandum to Registered Blood and Source Plasma
Establishments, Revision of FDA Memorandum of August 27,1982:
Requirements for Infrequent Plasmapheresis Donors - 3/10/1995.
4 - FDA Guidance for Industry: Recommendations for Collecting
Red Blood Cells by Automated Apheresis Methods - Technical Correction
February 2001 - 2/13/2001.
Reference 5 - Murphy S. Platelet storage for transfusion. Seminars
in Hematology 1985 July; 22 (3): 165-77. Published
Reference 6 - Dumont LJ, VandenBroeke T. Seven-day storage
of apheresis platelets: report of an in vitro study. Transfusion.
2003 Feb; 43 (2): 143-50. Published
Reference 7 - Blajchman MA. Incidence and significance of the
bacterial contamination of blood components. Dev Biol 2002;
108: 59-67. Published
Reference 8 - Hillyer CD, Josephson CD, Blajchman, MA, Vostal
JG, Epstein JS, Goodman JL. Bacterial contamination of blood
components: risks, strategies, and regulation: Joint ASH and
AABB Educational Session in Transfusion Medicine. Hematology
2003; 575-89. Published
9 - ASBPO Donor Deferral Criteria: Drugs and Medication
Impact on Blood Donor Eligibility. www.tricare.osd.mil/asbpo/library/policies/downloads/medication_list.doc
Reference 10 - Patrono C, Coller B, Dalen JE, et al. Platelet-Active
drugs. The relationships among dose, effectiveness, and side
effects. Chest 2001 supplement; 119 (1): 39-63s. Published
11 - Federal Register, Proposed Rules, Vol. 50, No. 247,
December 24, 1985. continued
12 - FDA Guideline on General Principles of Process Validation,
May 1987, reprinted February 1993.
13 - FDA Guidance for Industry: Use of Sterile Connecting
Devices in Blood Bank Practices 11/22/2000.
14 - FDA Guideline for Quality Assurance in Blood Establishments,
July 11, 1995.
Reference 15 - Dumont LJ, Dzik WH, Rebulla P, et al. Practical
guidelines for process validation and process control of white-cell
reduced blood components: report of the Biomedical Excellence
for Safer Transfusion (BEST) working party of the International
Society of Blood Transfusion (ISBT). Transfusion 1996; 36: 11-20.
16 - CBER Device Clearances: http://www.fda.gov/cber/appr2002/2002approv.htm
Reference 17 - Brecher ME, Means N, Jere CS et al. Evaluation
of an automated culture system for detecting bacterial contamination
of platelets: an analysis with 15 contaminating organisms. Transfusion
2001 Apr; 41 (4): 477-482. Published
Reference 18 - McDonald CP, Roy A, Lowe P, et al. Evaluation
of the BacT/Alert automated blood culture system for detecting
bacteria and measuring their growth kinetics in leucodepleted
and non-leucodepleted platelet concentrates. VOX Sang. 2001
Oct; 81(3): 154-60. Published
Reference 19 - Brecher ME, Heath DG, Hay SN, et al. Evaluation
of a new generation of culture bottle using an automated bacterial
culture system for detecting nine common contaminating organisms
found in platelet components. Transfusion. 2002 Jun; 42(6):
20 - FDA Draft Guidance for Industry: Biological Product
Deviation Reporting for Licensed Manufacturers of Biological
Products Other than Blood and Blood Components - 8/10/2001.
Reference 21 - Lazarus EF, Browning J, Norman J, Oblitas J,
Leitman SF. Sustained decreases in platelet count associated
with multiple, regular plateletpheresis donations. Transfusion.
2001 June; 41: 756-761. Published
22 - Circular of Information for the Use of Human Blood
and Blood Components. American Association of Blood Banks, America’s
Blood Centers, American Red Cross, July, 2002.
23 - FDA Guidance for Industry: Changes to an Approved Application:
Biological Products: Human Blood and Blood Components Intended
for Transfusion or for Further Manufacture - 8/7/2001.
Reference 24 - Glaz J, Naus J, Wallenstein S. Scan Statistics
2001. Springer Publishing. Published